A recent survey commissioned by the OSUCCC—James found that, while most U.S. adults identify family history (DNA-based risk passed down through families) as a risk factor for colorectal cancer, other factors such as alcohol use, lack of physical activity, and an American diet that is high in fat and processed foods were less known.
NCI has launched a clinical trials network to evaluate emerging technologies for cancer screening. The Cancer Screening Research Network will support the Biden-Harris administration’s Cancer Moonshot by investigating how to identify cancers earlier.
Drugs that target a receptor on immune cells called activin receptor 1C may combat tumor-induced immune suppression and help patients’ immune systems fight back against cancer, according to a study by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg-Kimmel Institute for Cancer Immunotherapy.
A study led by researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with the University of Helsinki, Massachusetts General Hospital, and the Broad Institute of MIT and Harvard, sheds light on how variations in immune genetics influence lung cancer risk, potentially paving the way for enhanced prevention strategies and screening.
Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have built and demonstrated the potential efficacy of a new chimeric antigen receptor T-cell-based immunotherapy specifically designed to treat patients with cutaneous and rare subtypes of melanoma.Â
The Wistar Institute’s associate professor Mohamed Abdel-Mohsen demonstrated, with his lab and collaborators, a connection between viral damage to the gut and premature biological aging.Â
Magentiq-Eye Ltd., an Israel-based technology company founded in 2014, announced today a study on the performance of Magentiq-Colo CADe version has been published in Lancet Digital Health.
A novel three-drug combination achieved notable responses in patients with advanced HER2-negative breast cancer, according to new research directed by investigators from the Johns Hopkins Kimmel Cancer Center.Â
Researchers at the Spanish National Cancer Research Center and the 12 de Octubre University Hospital in Madrid have developed a new immunotherapy to treat multiple myeloma that shows, in the laboratory, to be more effective than the immunotherapy currently used as preferred treatment.
Patient-Reported Outcomes of participants in the phase II/III QUILT 3.032 study of N-803 plus BCG in BCG-unresponsive non-muscle invasive bladder cancer were published by the peer-reviewed journal Urology Practice.Â
